UCB files for Cimzia RA approval in Europe

UCB is taking its case to make Cimzia the first PEGylated anti-TNF biologic available to rheumatoid arthritis patients in front of the European Medicines Agency. Recently approved for Crohn's, Cimzia is one of the most closely watched RA therapies in late-stage development. And UCB has gathered data on the responses of 2,300 patients in late-stage trials.

"Along with a fast onset of action, Cimzia has been shown to rapidly reduce the rate of progression of joint damage and to improve measurements of patients' physical function," said Olav Hellebo, president of inflammation operations for UCB. "With millions of people suffering from rheumatoid arthritis across the globe, Cimzia, when approved, will provide a new and effective treatment option for this debilitating condition."

- read the UCB release

Related Articles:
UCB's Cimzia app gets data boost
Quick Cimzia launch overjoys UCB
UCB CEO plots strategy following Cimzia approval
FDA shocks UCB investors with Cimzia trial demand
Late-stage Cimzia trial for RA hits endpoints